BioCentury: FDA Peptide Plans Reinforce Concerns About Ideology and Politics Influencing Drug Safety
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.